The End of an Era: Shall We Move Forward?

被引：3

作者：

Dang, Chau ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 29期

关键词：

POSITIVE BREAST-CANCER; ADJUVANT TREATMENT; DOSE-DENSE; RANDOMIZED-TRIAL; CHEMOTHERAPY; CYCLOPHOSPHAMIDE; DOCETAXEL; FLUOROURACIL; PACLITAXEL; EPIRUBICIN;

D O I：

10.1200/JCO.2011.36.7417

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3849 / 3851

页数：3

共 23 条

[1]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[2] Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer [J].

Burnell, Margot ;

Levine, Mark N. ;

Chapman, Judith-Anne W. ;

Bramwell, Vivien ;

Gelmon, Karen ;

Walley, Barbara ;

Vandenberg, Ted ;

Chalchal, Haji ;

Albain, Kathy S. ;

Perez, Edith A. ;

Rugo, Hope ;

Pritchard, Kathleen ;

O'Brien, Patti ;

Shepherd, Lois E. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :77-82

[3] Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741 [J].

Citron, ML ;

Berry, DA ;

Cirrincione, C ;

Hudis, C ;

Winer, EP ;

Gradishar, WJ ;

Davidson, NE ;

Martino, S ;

Livingston, R ;

Ingle, JN ;

Perez, EA ;

Carpenter, J ;

Hurd, D ;

Holland, JF ;

Smith, BL ;

Sartor, CI ;

Leung, EH ;

Abrams, J ;

Schilsky, RL ;

Muss, HB ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1431-1439

[4]

Clarke M, 2008, LANCET, V371, P29, DOI 10.1016/S0140-6736(08)60069-0

[5]

COUDERT B, 2009, 32 ANN SAN ANT BREAS

[6] Docetaxel and paclitaxel in the treatment of breast cancer: A review of clinical experience [J].

Crown, J ;

O'Leary, M ;

Ooi, WS .

ONCOLOGIST, 2004, 9 :24-32

[7] Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials [J].

De Laurentiis, Michele ;

Cancello, Giuseppe ;

D'Agostino, Diego ;

Giuliano, Mario ;

Giordano, Antonio ;

Montagna, Emilia ;

Lauria, Rossella ;

Forestieri, Valeria ;

Esposito, Angela ;

Silvestro, Lucrezia ;

Pennacchio, Roberta ;

Criscitiello, Carmen ;

Montanino, Agnese ;

Limite, Gennaro ;

Bianco, Angelo Raffaele ;

De Placido, Sabino .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (01) :44-53

[8] Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2-Normal, Node-Positive Breast Cancer: BCIRG-005 Trial [J].

Eiermann, Wolfgang ;

Pienkowski, Tadeusz ;

Crown, John ;

Sadeghi, Saeed ;

Martin, Miguel ;

Chan, Arlene ;

Saleh, Mansoor ;

Sehdev, Sandeep ;

Provencher, Louise ;

Semiglazov, Vladimir ;

Press, Michael ;

Sauter, Guido ;

Lindsay, Mary-Ann ;

Riva, Alessandro ;

Buyse, Marc ;

Drevot, Philippe ;

Taupin, Henry ;

Mackey, John R. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (29) :3877-3884

[9] Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel:: Breast International Group 02-98 randomized trial [J].

Francis, Prudence ;

Crown, John ;

Di Leo, Angelo ;

Buyse, Marc ;

Balil, Ana ;

Andersson, Michael ;

Nordenskjold, Bo ;

Lang, Istvan ;

Jakesz, Raimund ;

Vorobiof, Daniel ;

Gutierrez, Jorge ;

van Hazel, Guy ;

Dolci, Stella ;

Jamin, Sophie ;

Bendahmane, Belguendouz ;

Gelber, Richard D. ;

Goldhirsch, Aron ;

Castiglione-Gertsch, Monica ;

Piccart-Gebhart, Martine .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (02) :121-133

[10]

Hudis C, 2005, BREAST CANCER RES TR, V94, pS20

← 1 2 3 →